ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 919

IL-17 Receptor a Signaling Impedes NF-ĸB p50/p50 Repressor and Subverts B-Cell Anergy in BXD2 Mice

Jennie Hamilton1, Qi Wu2, PingAr Yang3, Bao Luo4, Woongjai Won5, Shanrun Liu6, Jun Li7, Hui-Chen Hsu2 and John D. Mountz8,9, 1Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, 7Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Birmingham VA Medical Center, Birmingham, AL, 9Department of Medicine, University of Alabama at Birmingham, birmingham, AL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cell tolerance and autoimmune diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: B Cell Biology and Targets in Autoimmune Disease I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: In autoimmune prone BXD2 mice, abnormally upregulated IL-17 acts through NF-ĸB p65 role to promote the spontaneous germinal center response and autoantibody production. Recently, a pre-germinal center defect in the early transitional B cell development of autoimmune BXD2 mice was identified. This defect was characterized by accelerated B cell development, a feature which was normalized by IL-17RA deficiency on the BXD2 background. The hypothesis of this work is that IL-17 induced NF-ĸB regulates transitional B cell development

Methods: Using a B cell antigen tetramer, La13-27 autoreactive B cells from the spleens of B6, autoimmune wild-type (WT) BXD2, and BXD2-Il17ra–⁄– mice were analyzed by FACS for the development of CD93+ transitional B cell subsets. Intracellular phospho-flow was used to determine levels of phospho-p65 (p-p65) and total phospho-tyrosine following anti-IgM (5 µg/mL) stimulation at different time points. Super-resolution molecular imaging (STORM) was carried out to visualize p65 and p50 in BXD2-Il17ra–⁄– B cells. WT BXD2 and BXD2-Il17ra–⁄– were treated in vivo with AdIL-17 or AdIL-17RA:Fc to enhance or block endogenous IL-17RA signaling, respectively. Activation vs anergic responses were assessed by Dojindo cell survival assay following anti-IgM stimulation. 

Results: There was an enhanced BXD2-Il17ra–⁄– transitional B cell anergy phenotype in vivo, which was characterized by a normalized La13-27+ transitional B cell development compared with WT BXD2. BXD2-Il17ra–⁄– B cells further exhibited strong anergic responses to BCR or TLR7 stimulation in vitro. The strong anergic phenotype of BXD2-Il17ra–⁄– mouse B cells was associated with a dramatically enhanced nuclear expression of NF-ĸB1 (p50) and down-modulation of NF-ĸB p-p65. Super-resolution imaging supported increased p50 homodimer presence in the nucleus of BXD2-Il17ra–⁄– B cells relative to WT BXD2. In vivo injection of AdIL-17 in pre-disease BXD2 mice enhanced anti-IgM induced survival and anergy loss. Surprisingly, despite normal expression of BAFF-R on transitional and mature B cell subsets, BlyS cannot reverse the anergic response of BXD2-Il17ra–⁄– B cells to BCR stimulation. Analysis of the expression of IL-17RA in the B-cell subsets in BXD2 mice showed that IL17RA is strongly upregulated in transitional T2 (CD93+IgM+CD23+) and germinal center (PNA+Fas+) B cells. Single cell analysis of T2 B cells revealed the co-expression of Il17ra with B-cell activation gene, Bclxl.

Conclusion: Our results suggest that, in BXD2-Il17ra–⁄– B cells, the anergy phenotype is established at the transitional stage. In these B cells, stimulus-specific transcription repressive p50/p50 homodimers may act as a master transcriptional regulator to counteract pro-activation/survival NF-ĸB signaling provided by other major B-cell stimulators. Reagents that can promote the NF-ĸB p50/p50 repressome complex may be a novel strategy to enhance B-cell tolerance for autoimmunity. *(Supported by NIH R01AI071110, R01AI083705, P30AR048311, T32 AI007051, VA Merit Review grant 1I01BX000600, Lupus Research Institute, Lupus Foundation of America. Il17ra–⁄– mice were a generous gift from Amgen).


Disclosure: J. Hamilton, None; Q. Wu, None; P. Yang, None; B. Luo, None; W. Won, None; S. Liu, None; J. Li, None; H. C. Hsu, None; J. D. Mountz, None.

To cite this abstract in AMA style:

Hamilton J, Wu Q, Yang P, Luo B, Won W, Liu S, Li J, Hsu HC, Mountz JD. IL-17 Receptor a Signaling Impedes NF-ĸB p50/p50 Repressor and Subverts B-Cell Anergy in BXD2 Mice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/il-17-receptor-a-signaling-impedes-nf-kb-p50p50-repressor-and-subverts-b-cell-anergy-in-bxd2-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-17-receptor-a-signaling-impedes-nf-kb-p50p50-repressor-and-subverts-b-cell-anergy-in-bxd2-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology